Yuheng Pharmaceutical: Signed a technology transfer contract and paid 14.15 million yuan.

Yu Heng Pharmaceutical announced that the company has signed a "Technology Transfer Agreement" with Capital Medical University, acquiring the patent rights of a derivative of quinoline and its synthesis method and application for 14.15 million RMB. This cooperation aims to achieve resource sharing, complementary advantages, promote the transformation of innovative drug research results, and help the company layout in the field of innovative drug products. The signing of the contract does not require the approval of the board of directors and shareholders' meeting. This cooperation will not have a significant impact on the company's financial condition and operating performance for the current year, but the impact on future operating performance will depend on the progress of the subsequent projects.